Q1 Earnings Estimate for Quanterix Issued By Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX) – Investment analysts at Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of Quanterix in a research note issued to investors on Monday, March 17th. Leerink Partnrs analyst P. Souda now expects that the company will earn ($0.69) per share for the quarter, down from their prior estimate of ($0.58). The consensus estimate for Quanterix’s current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($1.05) EPS.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $35.16 million during the quarter, compared to analyst estimates of $34.93 million.

Separately, Canaccord Genuity Group dropped their target price on Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday.

Quanterix Price Performance

Shares of NASDAQ:QTRX opened at $7.24 on Thursday. The company has a market capitalization of $278.91 million, a price-to-earnings ratio of -6.83 and a beta of 1.34. Quanterix has a 1 year low of $6.30 and a 1 year high of $26.18. The business’s 50-day moving average is $8.23 and its 200-day moving average is $10.88.

Institutional Trading of Quanterix

A number of institutional investors have recently added to or reduced their stakes in QTRX. Resona Asset Management Co. Ltd. bought a new position in shares of Quanterix in the 4th quarter worth $55,000. Tower Research Capital LLC TRC boosted its stake in shares of Quanterix by 219.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company’s stock valued at $61,000 after purchasing an additional 3,915 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Quanterix in the 4th quarter worth approximately $66,000. Canada Pension Plan Investment Board increased its stake in shares of Quanterix by 64.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company’s stock worth $108,000 after acquiring an additional 4,000 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new position in shares of Quanterix during the fourth quarter valued at approximately $108,000. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.